Health Care·Biotechnology·$6.4B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.57 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.57 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed cautious optimism about their pipeline and future developments. They did not provide specific guidance for the upcoming quarters.
Management highlighted ongoing efforts in drug development and potential future milestones.
They emphasized the importance of upcoming clinical trials.
The earnings report indicates that Protagonist Therapeutics is still in the development phase, with no revenue reported. Despite missing on EPS, the stock rose by 1.59%, likely due to positive sentiment around their ongoing clinical trials and drug development efforts. Investors may be encouraged by management's focus on future milestones.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
ZTO EXPRESS CAYMAN I Class A ADR
Mar 12, 2019